The University of Hong Kong has successfully developed a new influenza A vaccine

Recently, the University of Hong Kong has successfully developed a new influenza A vaccine The inoculated mice can prevent the infection of a variety of a influenza viruses including h7n9 A avian influenza virus The results were published in the international academic journal Proceedings of the American Academy of Sciences on April 1 However, the new vaccine has not yet been carried out in human clinical trials, and has not been available for the time being The research team has successfully developed a new type A influenza vaccine with attenuated vaccinia virus as the carrier This active recombinant vaccine (Wyeth / IL-15 / 5flu) can simultaneously express the antigen proteins of several A-type avian influenza virus strains (H5N1), and induce the immune response by using the cytokine IL-15 protein This vaccine technology is very hopeful to be used as a new strategy against influenza A virus According to reports, the attenuated vaccinia virus is quite effective for the development of vaccines, because it is also used for the manufacture of human smallpox vaccine, so far more than one billion doses have been used As a result, when the demand for vaccination has increased due to the influenza pandemic, the new vaccine can be mass produced using existing production equipment The international research team also includes Dr Liyanage P Perera and Dr Thomas A Waldmann from the National Cancer Institute of the National Institutes of health.